Phase II Trial of Thalidomide, Irinotecan and Gemcitabine in Chemonaive Patients with Advanced Non-Small Cell Lung Cancer

被引：9

作者：

Jazieh, A. R. ^{[1
,2
]}

Komrokji, R. ^{[1
]}

Gupta, A. ^{[1
]}

Patil, S. ^{[3
]}

Flora, D. ^{[4
]}

Knapp, M. ^{[5
]}

Issa, M. ^{[2
]}

Karim, N. Abdel ^{[1
]}

机构：

[1] Univ Cincinnati, Cincinnati, OH USA

[2] King Abdul Aziz Med City, Riyadh, Saudi Arabia

[3] Univ Memphis, Memphis, TN 38152 USA

[4] Oncol Hematol Oncol Care, Cincinnati, OH USA

[5] Mid Ohio Hematol Oncol, Columbus, OH USA

来源：

CANCER INVESTIGATION | 2009年 / 27卷 / 09期

关键词：

Thalidomide; non small cell lung cancer; chemotherapy; angiogenesis inhibitor; SOLID TUMORS; CHEMOTHERAPY; ANGIOGENESIS; COMBINATION; BEVACIZUMAB; CARBOPLATIN; PACLITAXEL; PLATINUM; FUTURE;

D O I：

10.3109/07357900801944856

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This study aim was to determine the efficacy and safety of the combination of Gemcitabine 1000 mg/m(2) day 1 & 8 and Irinotecan 100 mg/m(2) day 1 & 8 with escalating dose of thalidomide in chemonaive patients with advanced non-small cell lung cancer. Among the 20 patients who met eligibility criteria and received treatment, two patients (10%) experienced partial response and 14 (70%) experienced stable disease. The median time to disease progression was 4 months (95% CI: 2.8-6.6). The 1 year and 2 year survival rates were 36% and 27%, respectively. This combination is active in advanced NSCLC with manageable toxicity profile.

引用

页码：932 / 936

页数：5

共 22 条

[21] Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer [J].

Schiller, JH ;

Harrington, D ;

Belani, CP ;

Langer, C ;

Sandler, A ;

Krook, J ;

Zhu, JM ;

Johnson, DH .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (02) :92-98

[22] Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer [J].

Sridhar, SS ;

Shepherd, FA .

LUNG CANCER, 2003, 42 :S81-S91

← 1 2 3 →